HL is involved in HDL metabolism as well as being responsible for the metabolism of apolipoprotein B-containing lipoproteins (especially intermediate-density lipoproteins [IDLs] and large low-density lipoproteins [LDLs]). 5 Higher concentrations and activity of HL, as TG hydrolase, have been associated with increased levels of small dense LDL (sdLDL) 6-8 and lower levels of HDL. 7,8 EL is primarily involved in HDL metabolism, and higher concentrations have been correlated with lower HDL levels. 9,10 Moreover, recently it has been shown that EL activity is responsible for the low HDL-C levels in patients who undergo hemodialysis. 11 Alterations in the levels of plasma lipoproteins (high LDL-C and low HDL-C) are hallmarks of cardiovascular disease. Several comorbidities including diabetes mellitus, obesity, and metabolic syndrome (MS) have been shown to increase the risk of cardiovascular disease, 12 in part because of Objective-To assess the phospholipase activity of endothelial (EL) and hepatic lipase (HL) in postheparin plasma of subjects with metabolic syndrome (MS)/obesity and their relationship with atherogenic and antiatherogenic lipoproteins. Additionally, to evaluate lipoprotein lipase (LPL) and HL activity as triglyceride (TG)-hydrolyses to complete the analyses of SN1 lipolytic enzymes in the same patient. Approach and Results-Plasma EL, HL, and LPL activities were evaluated in 59 patients with MS and 36 controls. A trend toward higher EL activity was observed in MS. EL activity was increased in obese compared with normal weight group (P=0.009) and was negatively associated with high-density lipoprotein-cholesterol (P=0.014 and P=0.005) and apolipoprotein A-I (P=0.045 and P=0.001) in control and MS group, respectively. HL activity, as TG-hydrolase, was increased in MS (P=0.025) as well as in obese group (P=0.017); directly correlated with low-density lipoproteincholesterol (P=0.005) and apolipoprotein B (P=0.003) and negatively with high-density lipoprotein-cholesterol (P=0.021) in control group. LPL was decreased in MS (P<0.001) as well as in overweight and obese compared with normal weight group (P=0.015 and P=0.004, respectively); inversely correlated %TG-very low-density lipoproteins (P=0.04) and TG/ apolipoprotein B index (P=0.013) in control group. These associations were not found in MS. Conclusions-We describe for the first time EL and HL activity as phospholipases in MS/obesity, being both responsible for high-density lipoprotein catabolism. Our results elucidate part of the remaining controversies about SN1 lipases activity in MS and different grades of obesity. The impact of insulin resistance on the activity of the 3 enzymes determines the lipoprotein alterations observed in these states. (Arterioscler Thromb Vasc Biol. 2014;34:669-675.)
L ipoprotein lipase (LPL), hepatic lipase (HL), and endothelial lipase (EL) constitute a family of lipases involved in lipoprotein metabolism. These enzymes share a similar sequence structure at the genetic and protein level, thus indicating a common ancestral origin. However, they are expressed in different tissues and act on different lipoprotein substrates, indicating that they may have evolved to specific roles. 1 The 3 proteins are heparin-binding lipases anchored to the endothelial surface and mediate the hydrolysis of triglycerides (TG) and phospholipids (PL) at the SN1 position within circulating lipoproteins. Lipid hydrolysis results in structural changes within the lipoprotein species, which affects their removal from the plasma and releases fatty acids to be taken up by tissues. Although the 3 lipases have both TG and PL lipase activity, LPL is predominantly a TG-lipase, EL principally hydrolyses PL, and HL has an intermediate TG and PL lipase activity. 2 LPL is responsible for the hydrolysis of chylomicrons and very lowdensity lipoproteins (VLDLs). Lower LPL activity has been associated with severe hypertriglyceridemia accompanied by low levels of high-density lipoprotein-cholesterol (HDL-C). 3, 4 the changes in lipoprotein profile, including increased levels of TG rich lipoproteins, low levels of HDL-C, and increased levels of sdLDL. This profile, characteristic of insulin resistance (IR) states, is mainly attributed to abdominal obesity; however, it must be considered that the increase in body mass index does not always reflect IR. Additionally, there is evidence that weight change and IR individually can affect the atherogenic plasma lipid profile. 13, 14 The behavior of LPL and HL (as TG hydrolases) has been widely studied in IR states and obesity [15] [16] [17] [18] ; however, to our knowledge, EL and HL activities, as phospholipases, have never been evaluated in these situations. The altered lipoprotein profile observed in patients with IR and during obesity could be in part a consequence of differing lipolysis of lipoproteins in these states. Furthermore, there are still controversies about the SN1 lipases activity in different grades of obesity. [19] [20] [21] [22] Our aim was to assess the phospholipase activity of EL and HL in postheparin plasma of subjects with MS/obesity and their relationship with atherogenic and antiatherogenic lipoprotein levels. Additionally, we evaluated LPL and HL activity as TG-hydrolyses to ascertain the individual roles of the 3 plasma lipolytic enzymes in the same patient and the consequent lipoprotein profile.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Characteristics of the Study Population
The clinical and biochemical characteristics of MS and Control group are shown in Table 1 . In the MS group, 43 patients were women and 16 men; whereas in the control group, 20 were women and 16 were men. Patients with MS were older (P<0.001) and presented higher body mass index (BMI; P<0.001) and waist circumference (P<0.001) than controls.
Regarding lipid and lipoprotein profile, the MS group presented higher TG (P<0.001), total cholesterol (P=0.042), LDL-C (P<0.001), and apolipoprotein B-100 (P=0.002), and lower HDL-C and apolipoprotein A-I levels (P<0.001).
With reference to IR and inflammatory state, as expected, values of glucose, insulin, homeostasis model assessment for insulin resistance index (HOMA-IR), TG/HDL-C, free fatty acids (FFA), and high-sensitivity C-reactive protein were higher (P<0.001), and adiponectin was lower in patients with MS compared with controls (P<0.001; Table 2 ). Furthermore, in both groups, VLDL, IDL, and sdLDL were isolated and characterized. As shown in Table 3 , in patients with MS, a prevalence of larger VLDL was observed, enriched in TG, as well as an increase of remnants and sdLDL.
The baseline characteristics of the subjects divided according to obesity degree are shown in Table 4 .
Phospholipase Activities
EL Activity
EL activity was evaluated in control and MS group. A trend toward higher EL activity was observed in MS; however, it did not reach significance: 0.92 (0.09-1.93) versus 1.11 (0.15-3.06) μmol FFA/mL post heparin plasma per hour (PHP.h), P=0.097 ( Figure 1A ). There was no difference in EL activity between men and women: 1.25 (0.29-3.06) versus 1.0 (0.09-2.53) μmol FFA/mL PHP.h, P=0.330.
EL activity was not associated with age (r=−0.167; P=0.147) nor with waist circumference (r=0.183; P=0.126). Given the direct association between EL activity and BMI in the whole population (r=0.291; P=0.01), we analyzed the behavior of the enzyme according to the obesity degree of the subjects. EL activity was significantly increased in obese (OB) group compared with normal weight (NW) group: 1.25 (0.15-3.06) versus 0.71 (0.09-1.93) μmol FFA/mL PHP.h, P=0.009 ( Figure 1B ). Although no correlations with age and sex were observed, we performed an ANCOVA analysis including both variables. Difference between OB and NW group persisted significantly (F=6.9, P=0.004 and F=4.8, P=0.01, respectively).
Additionally, in the control and MS groups, EL activity was negatively associated with HDL-C (r=−0.369, P=0.014 and r=−0.480, P=0.005, respectively) and apolipoprotein A-I Data are expressed as mean±SD or median (range) for skewed distributed data. apoA-I indicates apolipoprotein A-I; apoB, apolipoprotein B; BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; M, men; MS, metabolic syndrome; Total-C, total cholesterol; and W, women.
(r=−0.311, P=0.045 and r=−0.559, P=0.001, respectively), highlighting the role of EL on HDL catabolism. Similarly, in both groups, EL activity was positively correlated with insulin (r=0.301, P=0.05 and r=0.390, P=0.027, respectively) and HOMA-IR (r=0.310, P=0.047 and r=0.413, P=0.019, respectively). In contrast, EL activity negatively correlated with adiponectin (r=−0.515; P=0.006) only in control group.
Given that there was no difference in EL activity between the MS and control groups, but a positive association between EL activity and HOMA-IR was observed, individuals were divided according to HOMA-IR quartile. The quartiles were defined according to the following range: quartile 1, HOMA-IR≤1.02; quartile 2, 1.03<HOMA-IR≤1.76; quartile 3, 1.77<HOMA-IR≤3.30; and quartile 4, HOMA-IR≥ 3.31. It was observed that individuals with the highest grade of IR (quartile 4) showed a significant increase in EL activity with respect to individuals with the lowest grade of IR (quartile 1; P<0.05; Figure 1C ).
HL Activity
When HL was evaluated as phospholipase, there was no difference between control and MS groups: 5 Although no difference in HL activity was found between groups, regarding lipoprotein profile, in the control group, HL activity was negatively correlated with HDL-C (r=−0.639; P=0.001) and apolipoprotein A-I levels (r=−0.623; P=0.001) whereas in the MS group only a tendency with HDL-C was observed (r=−0.281; P=0.062). An inverse association with adiponectin was observed only in the control group (r=−0.441; P=0.021).
Effect of EL and HL as Phospholipase on HDL
Given that EL and HL as phospholipase were associated with HDL-C, the impact of both enzymes activities on HDL-C was analyzed through a multivariate regression analysis to distinguish the contribution of each one. In the MS group, HDL-C decrease remained mainly associated with EL activity (β=−0.35; P=0.01).
TG-Lipase Activities
HL Activity
As expected, HL activity, as TG-hydrolase, was increased in the MS group compared with the control group: 14.53±6.33 versus 11.26±4.92 μmol FFA/mL PHP.h, P=0.025 (Figure 2A) . Similarly to its activity as phospholipase men presented higher values of HL than women (16.7±5.8 μmol FFA/mL PHP.h versus 11.8±5.5 μmol FFA/mL PHP.h, P<0.001). With reference to obesity degree, HL activity as TG-hydrolase was significantly increased in the OB group compared with the NW group: 15.0±6.3 versus 10.8±4.8 μmol FFA/mL PHP.h, P=0.017 ( Figure 2B ). HL activity was not associated with age (r=0.031; P=0.802). With reference to lipids and lipoproteins profile, in the control group, HL activity was directly correlated with LDL-C (r=0.526; P=0.005), apolipoprotein B (r=0.560; P=0.003), and negatively correlated with HDL-C (r=−0.442; P=0.021). These correlations were not found in the MS group in whom HL activity showed a weak inverse correlation with IDL-C (r=−0.365; P=0.040). With respect to IR markers, HL activity was positively associated with insulin (r=0.378; P=0.011) and HOMA-IR (r=0.323; P=0.032) in MS group.
Given that HL activity was higher in men than in women, we performed an ANCOVA analysis including sex as an independent variable. Differences in HL activity remained significant between the MS group and controls (F=8.9, P=0.004) and among obesity degree groups (F=6.4, P=0.003). Although HL activity was not associated with age, we also included this variable in the ANCOVA analysis. Differences in HL activity persisted significantly between the MS group and controls (F=5.2, P=0.02) and among obesity degree groups (F=4.1, P=0.02).
It is important to point out that HL as TG-hydrolase directly correlated with HL as phospholipase: r= 0.79, P<0.001.
LPL Activity
Patients with MS presented lower LPL activity than controls: 0.75 (0.04-2.10) versus 1.38 (0.56-2.58) μmol FFA/mL PHP.h, P<0.001. In the whole population, there was no difference in LPL activity between men and women: 0.99 (0.26-1.55) versus 1.15 (0.04-2.58) μmol FFA/mL PHP.h, P=0.160, and it was not associated with age (r=−0.171; P=0.173).
When obesity degree was considered, LPL activity was significantly decreased in OW group: 0.81 (0.19-1.34) μmol FFA/mL PHP.h and OB group: 0.75 (0.04-2.10) μmol FFA/mL PHP.h compared with NW group: 1.54 (0.56-2.58) μmol FFA/mL PHP.h, P=0.015 and P=0.004, respectively (Figure 3) .
Although no correlations with age and sex were observed, we performed an ANCOVA analysis including age and sex as independent variables. Differences in LPL activity remained significant between the MS and control groups (F=10.7, P=0.002 and F=12.1, P=0 .001, respectively) and among obesity degree groups (F=5.9, P=0.004 and F=6.6, P=0.002, respectively).
The expected relationship between LPL activity and %TG-VLDL (r=−0.636, P=0.04) and TG/apolipoprotein B index (r=−0.783, P=0.013) was indeed found in the control group. However, in this group, only weak associations between LPL activity and insulin (r=−0.462, P=0.04) and HOMA-IR index (r=−0.468, P=0.037) were found.
Discussion
In the present study, we evaluated the role of EL, HL, and LPL activity in the lipoprotein abnormalities associated with MS and obesity. It is important to highlight that this is the first time that EL and HL as phospholipases were evaluated in MS and obesity. Moreover, to our knowledge, this study is the first that reports all 3 lipoprotein lipases activity in the same population.
It is well known that obesity and associated IR are main contributors to cardiovascular disease. 23 These relationships are directly linked with lipids and lipoproteins alterations which include elevated TG and lower HDL-C.
In this study, we showed for the first time that EL activity is increased in individuals with higher obesity degree and is associated with lower HDL-C and apolipoprotein A-I levels.
Previous studies have shown that overexpression of EL in mice results in a dramatic decrease in HDL-C and apolipoprotein A-I levels, leading to the production of smaller HDL particles. 10 Furthermore, several studies in human plasma demonstrated higher expression of EL in MS 24 and obesity 25 associated with a significant decrease of HDL-C levels. In this study, we evaluated EL activity, and no significant difference between controls and patients with MS was found. However, there was a trend toward increase in EL activity in MS, and the lack of significance may reflect the inherent high assay variability. In this respect, a direct EL activity assay where HL is removed by immunoprecipitation would be useful. Further studies including larger number of patients would possibly allow us to obtain significant differences between groups. When the subjects were analyzed according to their obesity degree, those with the highest obesity grade presented the highest EL activity. Our results support the previous findings of Badellino et al 26 who showed that plasma EL concentration is positively correlated with markers of adiposity, such as BMI and waist circumference in healthy individuals. Part of the association observed between EL and obesity could be attributed to the impact of the IR state, corroborated by the correlation between EL activity and the HOMA index in individuals with MS and controls. This finding is held up by the increased EL activity observed at the highest HOMA quartile. Additionally, it is important to highlight that, in contrast to LPL and HL, EL activity was associated with lower HDL-C and apolipoprotein A-I levels in individuals with MS and controls. Although IR would be the best predictor of EL behavior, this study is the first to report an inverse association between EL activity and adiponectin in individuals without MS. It should be noted that adiponectin was also associated with HL phospholipase activity, suggesting a possible role of this cytokine in phospholipase activity regulation. Until now, it has only been described an inverse association between EL concentration and adiponectin levels in healthy individuals. 26 However, in vitro studies showed that tumor necrosis factor-α may stimulate EL secretion; thus, adiponectin would affect EL indirectly by inhibiting tumor necrosis factor-α. 26 Further studies are necessary to elucidate this finding.
Regarding HL, as expected, TG-activity was increased in MS group. HL activity seems to be regulated by several factors including age 27 and sex. 27, 28 It has been reported that men have twice as high HL activity as women 29 and, in accordance, we have observed that men presented higher HL activity than women; however, the higher HL activity in the MS group was independent of sex and age. Even more, HL activity was increased in the OB group; these results suggest that the severe states of obesity would be implicated in the regulation of the enzyme, as described in other studies. 21 The specific mechanism that links HL activity to hyperinsulinemia and IR remains unclear. It is known that patients with type 1 diabetes mellitus present low HL activity, 17 and that chronic hyperinsulinemic states show increased activity of the enzyme. 18 It was suggested that secondary factors might contribute to the regulation of HL in obesity and IR states 30 ; in fact in our study, only in the MS group, a weak association between HL activity and IR markers was found. HL activity directly correlated with atherogenic lipoprotein profile only in the control group. When analyzing HL as phospholipase, no differences between groups, MS or obesity degree, were observed. HL phospholipase activity inversely correlated with HDL and apolipoprotein A-I levels in Control group. HL enzyme activities, as TG-lipase and phospholipase, were directly correlated within individuals. The differences in importance within a disease state may reflect their different in vivo substrates: VLDL and LDL for TG-lipase activity and HDL for phospholipase activity.
According to our results, HDL-C levels would be influenced by phospholipase activities of EL as well as HL, with EL mainly responsible for HDL catabolism. Both HL and EL variants have been shown to affect HDL-C. 31, 32 Because often they are similarly regulated, it is important to note which is the predominant determinant of HDL-C. The present data along with our previous analysis of individuals undergoing hemodialysis 11 suggest that HDL-C decrease is mainly associated with EL activity. Our findings extend previous reports about factors that can modulate HDL-C levels, such as lecithin cholesterol acyl transferase, and ATP-binding cassette subfamily A member 1 expression, among others. 33 With reference to LPL, this study shows a significant decrease in plasma activity in individuals with MS. Previous studies reported lower LPL mass in individuals with MS, 14 as well as negative correlations with BMI. 34 Our results of LPL activity in post heparin plasma are in agreement with the reported findings; we found a significant decrease from OW situations with a clear decrease in OB. Recent studies have shown that the expression and activity of LPL in post heparin plasma is lower in obese patients with diabetes mellitus with respect to obese individuals without diabetes mellitus and controls. 20 Moreover, a decrease in LPL gene expression in the visceral adipose tissue from morbidly obese individuals compared with obese and lean individuals has been reported. 35 In our study, we observed that LPL activity was inversely associated with surrogate markers of IR only in individuals without MS. With reference to the role of LPL in VLDL catabolism, our data revealed the expected inverse correlation with VLDL-TG content and size in the control group; however, these associations were not found in the patients with MS. These results are in accordance with previous studies, which suggest that other factors have more important regulatory roles in the removal of postprandial lipoproteins in IR states. 36, 37 With respect to high-sensitivity C-reactive protein, in this study, no significant association between this chronic inflammation marker and lipolytic enzymes activity was found. Different studies have shown controversial results according to the effect of C-reactive protein on the expression and activity of the enzymes. 26, 30, 38, 39 In this study, the lack of association between high-sensitivity C-reactive protein and the lipolytic enzymes should not exclude more complex inflammatory mechanisms in the regulation of enzyme activity.
Finally, in this study, we describe for the first time the activity of the 3 main lipolytic enzymes, evaluated in the same population, highlighting the specific role of each one on the different lipoproteins metabolism. EL and HL as phospholipase are both responsible for HDL catabolism. Our results elucidate part of the remaining controversies about the SN1 lipases activity in different grades of obesity. The impact of IR and obesity on the 3 enzymes behavior (Table 5 ) determines the lipoproteins alterations in these pathological situations. Overall, lipolytic enzymes would be an interesting potential therapeutic target as a strategy to improve lipoprotein profile and reduce cardiovascular risk in IR and obese patients.
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